Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 7,724 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Completed Phase 2 Interventional Results available

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

NCT00186628
View directory record Official record
Conditions
Leukemia, Mast-Cell, Mantle-cell Lymphoma
Interventions
Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, Mycophenylate mofetil, Filgrastim, Granisetron, Solumedrol, Acetaminophen, Diphenhydramine, Hydrocortisone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 76 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 28, 2026, 9:31 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

NCT01199367
View directory record Official record
Conditions
Breast Cancer
Interventions
KW-2450 in combination with lapatinib and letrozole
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Long Beach, California • Los Angeles, California • Deerfield Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Phase 1 Interventional

Evaluating Patients With Varying Degrees of Renal Function

NCT00398307
View directory record Official record
Conditions
Renal Impairment
Interventions
S-1/Cisplatin
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
9
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 28, 2026, 9:31 AM EDT
Terminated Phase 1 Interventional

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

NCT06304636
View directory record Official record
Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Descartes-15
Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 28, 2026, 9:31 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

NCT02743611
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
Interventions
BPX-701, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Denver, Colorado • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Early Phase 1 Interventional

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT01980823
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Cancer of Breast
Interventions
Metformin, Atorvastatin, Breast surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of Extended Treatments for Drug Dependence

NCT00685659
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Intensive Outpatient Treatment, Adaptive telephone-based counseling, Adaptive telephone-based counseling plus incentives
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 28, 2026, 9:31 AM EDT
No Longer Available No phase listed Expanded access

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

NCT03594162
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
Interventions
iC9-CAR19 cells, AP1903, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years to 70 Years
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Phase 1 Interventional

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

NCT00482846
View directory record Official record
Conditions
Mucositis, Multiple Myeloma
Interventions
Palifermin, melphalan, questionnaire administration, autologous peripheral blood stem cell transplantation, quality-of-life assessment
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Examining the Relationship Between Acute Meal Intake and Inflammation in Children

NCT03597542
View directory record Official record
Conditions
Obesity, Inflammation
Interventions
Eggs and Carbohydrates
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
7 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 28, 2026, 9:31 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers

NCT02587442
View directory record Official record
Conditions
Acute Radiation Syndrome
Interventions
RadProtect®
Drug
Lead sponsor
Original BioMedicals Co. Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Phase 1Phase 2 Interventional

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)

NCT05757570
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Interventions
Povetacicept
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Cooper City, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Phase 2 Interventional Results available

Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)

NCT03168711
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Inosine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 28, 2026, 9:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07215234
View directory record Official record
Conditions
Geographic Atrophy
Interventions
SAR446597, Sham Comparator
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
31
States / cities
Peoria, Arizona • Scottsdale, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Phase 3 Interventional Results available

Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC

NCT00499109
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel, Vinorelbine, Carboplatin, Gemcitabine
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Lakeland, Florida • Leesburg, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Not applicable Interventional Results available

Visits Versus Telephone Calls for Postoperative Care

NCT02891187
View directory record Official record
Conditions
Satisfaction, Postoperative Complications, Pelvic Floor Disorder
Interventions
Telephone follow-up, Outpatient Clinic Visits
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Not applicable Interventional Results available

Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort

NCT02015221
View directory record Official record
Conditions
Chronic Venous Insufficiency
Interventions
Dual Action Pneumatic Compression Device, Standard Compression Garments
Device
Lead sponsor
Tactile Medical
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Colton, California • La Jolla, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Phase 2 Interventional Results available

The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer

NCT00487721
View directory record Official record
Conditions
Prostate Cancer
Interventions
Silibin-Phytosome
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 28, 2026, 9:31 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Emsella for Reducing tSUI After HOLEP

NCT07580404
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms, Enlarged Prostate (BPH)
Interventions
Emsella chair
Device
Lead sponsor
Northwestern University
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 9:31 AM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 28, 2026, 9:31 AM EDT
Withdrawn Not applicable Interventional

Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis

NCT01710293
View directory record Official record
Conditions
Lung Cancer, Bladder Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Breast Cancer
Interventions
Communication of Patients Lost to Follow-up to Providers
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Chicago, Illinois • Hines, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 28, 2026, 9:31 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RCT- Comparing Testimonial Versus Documentary Organ Donation Video Education

NCT02836301
View directory record Official record
Conditions
Organ Donation
Interventions
Control ending - Uplifting, Negative Consequences Ending, Unresolved Ending
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 28, 2026, 9:31 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

NCT02794571
View directory record Official record
Conditions
Advanced/Metastatic Tumors
Interventions
Atezolizumab, Tiragolumab, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 28, 2026, 9:31 AM EDT